Bone markers - New aspects

Clinical Laboratory

Volumn 54, Issue 11-12, 2008, Pages 461-471

  Cremers, Serge ^a   Bilezikian, John P ^a   Garnero, Patrick ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; ALPHA ALPHA CARBOXY TERMINAL TELOPEPTIDE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE SIALOPROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; DENOSUMAB; DEOXYPYRIDINOLINE; DICKKOPF 1 PROTEIN; HYDROXYPROLINE; OSTEOCALCIN; OSTEOPONTIN; PARATHYROID HORMONE[1-34]; PROCOLLAGEN TYPE I AMINOTERMINAL PROPEPTIDE; PROCOLLAGEN TYPE I CARBOXYTERMINAL PROPEPTIDE; PYRIDINOLINE; SCLEROSTIN; TARTRATE RESISTANT ACID PHOSPHATASE 5B; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

BONE METASTASIS; BONE TURNOVER; DATA ANALYSIS; DRUG ABSORPTION; FRACTURE; HUMAN; IMMUNOASSAY; LABORATORY AUTOMATION; MATHEMATICAL MODEL; MULTIPLE MYELOMA; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT CARE; PROCESS OPTIMIZATION; PROTEIN BLOOD LEVEL; QUALITY CONTROL; REVIEW; SINGLE DRUG DOSE;

AUTOMATION; BIOLOGICAL MARKERS; BONE AND BONES; BONE DISEASES; BONE REMODELING; COLLAGEN TYPE I; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HOMEOSTASIS; HUMANS; MODELS, BIOLOGICAL; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 60549117086     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
2. Ahmad AM, Thomas J, Clewes A, Hopkins MT, Guzder R, Ibrahim H, Durham BH, Vora JP, Fraser WD. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism. J Clin Endocrinol Metab. 2003;88(6): 2860-8.
3. Akesson K, Ljunghall S, Jonsson B et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 1995;10:1823-1829.
4. Alexandersen P, Peris P, Guañabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PA. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res. 2005; 20(4):588-95.
5. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD; Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19(8):1250-8.
6. Bauer DC, Garnero P, Hochberg MC et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006; 21:292-299.
7. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, and Bekker PJ. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-1228.
8. Brown JE, Cook RJ and Major P et al., Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59-69.
9. Bruyère O, Collette J, Delmas P et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal women. Maturitas 2003;44:259-265.
10. Chapurlat RD, Garnero P, Bréart G, Meunier PJ, Delmas PD. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000;27:283-286.
11. Chen JS, Seibel MJ, Zochling J et al. Calcaneal ultrasound but not bone turnover predicts fractures in vitamin D deficient frail elderly at high risk of falls. Calcif Tissue Int 2006;79:37-42.
12. Claudon A, Vergnaud P, Valverde C, Mayr A, Klause U, Garnero P. New Automated Multiplex Assay for Bone Turnover Markers in Osteoporosis. Clin Chem. 2008, In Press, available online.
13. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002 Jun;30(6):886-90.
14. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treatment Rev 2008; In press, available online.
15. Cremers S, Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 2006;66(16): 2031-2058.
16. Cremers S, Sparidans R, den HJ, Hamdy N, Vermeij P, Papapoulos S. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002;57:883-890.
17. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet. 2005;44 (6):551-70.
18. Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone. 2006;39(2):237-43.
19. Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB; Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92(4):1296-304.
20. Diel IJ, Solomayer EF, Seibel MJ, et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999;5:3914-3919.
21. Diel IJ, Solomayer EF, Seibel MJ, et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Ret 1999;5:3914-3919.
22. Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 2007;22:1656-1660.
23. Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 2000;17:826-833.
24. Garnero P, Dargent-Molina P, Hans D et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 1998;8: 563-569
25. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004; 4(1): 50-63.
26. Garnero P, et al. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000; 11 [Suppl 6]:S55-S65.
27. Garnero P, Hausher E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the Epidos prospective study. J Bone Miner Res 1996;11:1531-1538.
28. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-1536.
29. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2007; 54(1): 188-196.
30. Garnero P. New biochemical markers of bone turnover. IBMS Bonekey 2008; 5(3):84-102.
31. Gerdhem P, Ivaska KK, Alatalo SL et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19:386-393
32. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund K, Kalervo Vaananen H. Tartrate-resistant acid phosphatase 5b (TRAP 5b) as a marker of bone resorption. Clin Lab 2006;52(9-10):499-509.
33. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008;452(7187):571-9.
34. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone. 2007;40(3):723-9.
35. Holford N, Pillai G, Kaila, et al. PKPD model for cathepsin K inhibition and changes in bone turnover biomarkers, in particular NTX. Abstract 1015. Population Approach Group Europe (PAGE) meeting 2006. Brugge, Belgium.
36. Hollis BW. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr 2008;88(2): 507S-510S.
37. Hortin GL, Jortani SA, Ritchie JC, Valdes R, Chan D. Proteomics: a new diagnostic frontier. Clin Chem 2006;52(7):1218-1222
38. Huang HL, Stasyk T, Morandell S, et al. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TO/TOF and data validation by routine clinical assays. Electrophoresis 2006;27:1641-1650.
39. Ivaska KK, Gerdhem P, Akesson K, Obrant KJ. Bone turnover markers and prediction of fracture: nine-year follow-up study of 1040 elderly women. J Bone Miner Res 2007;22 [Suppl 1]: S21, Abstract 1073
40. Jin S, Shen J-N, Guo Q-C, et al. 2-D DIGE and MALDI-TOF-MS analysis of the serum proteome in human osteosarcoma. Proteomics Clin Appl 2007;1:272-285.
41. Johnell O, Oden A, de Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002;13:523-526.
42. Leeming DJ, Delling G, Koizumi M, Henriksen K, Karsdal MA, Li B, Qvist P, Tankó LB, Byrjalsen I. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1392-5.
43. Lemaire V, Tobin FL, Greller LD, Cho CR, Suva LJ. Modeling the interactions between osteoblast and osteoclast activities in bone emodelling. J Theor Biol. 2004 Aug 7;229(3):293-309.
44. Lipton A, Chapman JW, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel K, Ali SM, Pollak MN. Use of elevated bone turnover to predict bone metastasis. J Clin Oncol 2008;26S; abstr 591.
45. Lipton A, Cook RJ, Major P, Smith MR and Coleman RE, Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity, Oncologist 2007;12:1035-1043.
46. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008 (in press).
47. Loibl S, Konigs A, Kaufmann M, et al. PTHrP and bone sialo-protein as prognostic markers for developing bone metastases in breast cancer patients. Zentralbl Gynakol 2006;128:330-335.
48. Loibl S, Konigs A, Kaufmann M, et al. PTHrP and bone sialo-protein as prognostic markers for developing bone metastases in breast cancer patients. Zentralbl Gynakol 2006;128:330-335.
49. Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther. 2008;326(2):555-62.
50. Melton LJ III, Crowson CS, O'Fallon WM, Wahner HW, Riggs BL. Relative contribution of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 2003;18:312-318.
51. Nguyen T, Meier C, Seibel C. Variability in the measurement of biochemical markers of bone turnover. In: Seibel MJ, Robins SP, Bilezikian JP (eds) Dynamics of bone and cartilage metabolism. 2nd Edition; Academic Press, San Diego; 2006.
52. Peterson MC and Riggs MM. Calcium homeostasis and bone remodeling: development of an integrated model for evaluation and simulation of therapeutic responses to bone-related therapies. PAGE (Population Approach Group in Europe) Sixteenth Meeting; 2007 Jun 13-15; Copenhagen, Denmark. PAGE, Copenhagen, Denmark.
53. Peterson MC and Riggs MM. Calcium homeostasis and bone remodeling: development of an integrated model for evaluation and simulation of therapeutic responses to bone-related therapies. PAGE (Population Approach Group in Europe) Sixteenth Meeting; 2007 Jun 13-15; Copenhagen, Denmark. PAGE, Copenhagen, Denmark.
54. Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer RC, Steimer JL. A semimechanistic and mechanistic population PKPD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol. 2004;58(6):618-31.
55. Proteomics of Human Body Fluids. Visith Thongboonkerd, Editor.,Totowa, NJ: Humana Press, 2007
56. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002 Jul;31(1):57-61.
57. R.E. Coleman, P. Major and A. Lipton et al., Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935.
58. Reginster JY, Gieschke R. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. Curr Drug Metab. 2006;7(7):827-36.
59. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessmen. J Clin Endocrinol Metab 2005;90(11):6323-31.
60. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000;11:76-82.
61. Schmidt-Gayk H, Spanuth E, Kötting J, et al. Performance evaluation of automated assays for beta-crosslaps, N-mid-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med 2004;42(1):90-95.
62. Schousboe JT, Bauer DC, Nyman JA, Kane RL, Melton LJ, Ensrud KE. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 2007;18:201-210.
63. Seibel M. Biochemical markers of bone turnover: Part 1: Biochemistry and variability. Clin Biochem Rev 2005; 26(4): 97-122.
64. Seibel MJ, Lang M, Geilenkeuser W-J. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001;47: 1443-1450.
65. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005;20: 1813-1819
66. Szulc P, Delmas P. Biochemical markers of bone turnover: potential use in the investigation and management of post-menopausal osteoporosis. Osteoporosis Int 2008; In press, available online.
67. Tan X, Cai D, Wu Y, et al. Comparative analysis of serum proteosomes: discovery of proteins associated with osteonecrosis of the femoral head. Translational Research 2006; 148(3):114-119.
68. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483-94.
69. Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P. Predictors of fractures in elderly women. Osteoporos Int 2000; 11:134-140.
70. V. Hirsh, P.P. Major and A. Lipton et al., Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity, J Thorac Oncol 2008;3:228-236.
71. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW. Sclerostin is an osteocyte-ex-pressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199(6):805-14.
72. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P, Garnero P. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer. 2007;97(7):964-70.
73. Weel AEAM, Seibel MJ, Hofman A, Leeuwen JPTM, Pols HAP. Which fractures are associated with high bone resorption in elderly women: the Rotterdam study. J Bone Miner Res l999;14 [Suppl 1]:S160, Abstract 1110.
74. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(3):1013-9.